Key result
Melatonin supplementation improves cardiometabolic risk, lowering fasting glucose by ~/dL.
Why the study?
Does melatonin supplementation improve cardiometabolic risk factors?
Meta-Analysis
Does melatonin supplementation improve cardiometabolic risk factors?
Answers are grounded in this paper and cite their sources.
Melatonin supplementation significantly improves multiple cardiometabolic risk factors, including systolic blood pressure, fasting blood glucose, and lipid profiles.
Background/Objectives: There is no definitive consensus regarding the effects of melatonin on cardiometabolic risk factors (CMRFs). This systematic review and dose–response meta-analysis of randomized controlled trials (RCTs) evaluated the impacts of melatonin supplementation on CMRFs, including anthropometric, lipid, glycemic, inflammatory, oxidative, and liver function parameters. Methods: A systematic search across multiple databases retrieved 63 eligible RCTs published up to October 2025. Results: This random-effects meta-analysis indicated that melatonin supplementation significantly reduced hip circumference (weighted mean difference (WMD): −1.18 cm, 95% confidence interval (CI): −2.28, −0.08), systolic blood pressure (WMD: −2.34 mmHg, 95% CI: −4.13, −0.55), fasting blood glucose (WMD: −11.63 mg/dL, 95% CI: −19.16, −4.10), low-density lipoprotein cholesterol (WMD: −6.28 mg/dL, 95% CI: −10.53, −2.03), total cholesterol (WMD: −6.97 mg/dL, 95% CI: −12.20, −1.74), C-reactive protein (WMD: −0.59 mg/L, 95% CI: −0.94, −0.23), malondialdehyde (WMD: −1.54 μmol/L, 95% CI: −2.07, −1.01), tumor necrosis factor-alpha (WMD: −1.61 pg/mL, 95% CI: −2.31, −0.90), interleukin-6 (WMD: −6.43 pg/mL, 95% CI: −10.72, −2.15), and alanine aminotransferase (WMD: −2.61 IU/L, 95% CI: −4.87, −0.34). Supplementation with melatonin substantially increased serum total antioxidant capacity (WMD: 0.15 mmol/L, 95% CI: 0.08, 0.22) and high-density lipoprotein cholesterol (WMD: 2.04 mg/dL, 95% CI: 0.50, 3.57). No significant effects of melatonin were observed on body weight, waist circumference, body fat percentage, body mass index, fasting insulin, homeostasis model assessment of insulin resistance, hemoglobin A1c, triglycerides, diastolic blood pressure, aspartate aminotransferase, or gamma-glutamyl transferase. Conclusions: Melatonin supplementation significantly ameliorated multiple CMRFs.
No takes yet. Share an insight, caveat, or question.
Mohammadi et al. (2025) conducted a meta-analysis in Cardiometabolic risk factors. Melatonin supplementation vs. Control was evaluated on Fasting blood glucose (WMD -11.63 mg/dL, 95% CI -19.16, -4.10). Melatonin supplementation reduced multiple cardiometabolic risk factors, including fasting blood glucose and systolic blood pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: